تقييم المستويات المصلية لعامل النمو الوعائي البطاني VEGF لدى مرضى الخباثات الدموية

Abstract EN

Vascular endothelial growth factor VEGF plays a key role in angiogenesis and inducing vascular permeability, which make it one of the most important factors participating in solid tumors development and metastasis.

And with regard to hematological malignancies do not develop as compact tumor mass, the necessity for angiogenesis was not as readily apparent as for solid tumors.

However, several studies provide evidences for angiogenesis induction in neoplasias of hematological malignancies similar to angiogenesis in solid tumors.

This study was aimed to evaluate serum VEGF levels in 149 patients with hematological malignancies whom divided to tow groups: respond to therapy group which contain 75 patients and non respond to therapy group which contain 74 patients by comparing them with control group (26 apparently normal subjects).

Serum VEGF levels in hematological malignancies patients whom do not respond to therapy were higher than whom respond to therapy and control group with statistically significant difference, that indicate to activating angiogenesis induction in the predominant sites for oncogenesis in most hematological malignancies which are marrow and lymphatic tissues.